Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing precision immunology therapies for patients with immune-mediated diseases. The company operates within the biotechnology and pharmaceutical research and development industries, with an emphasis on discovering and advancing oral small-molecule medicines that target validated immune pathways.
The company’s primary value driver is its proprietary pipeline of immunology drug candidates, led by ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor being developed for autoimmune and inflammatory diseases. Alumis is positioned as a precision immunology company that integrates deep biological insight with targeted drug design, aiming to differentiate itself through selectivity, safety, and oral dosing. The company was founded in 2021 and incubated by Third Rock Ventures, evolving from early research-stage development into a publicly listed clinical-stage organization following its initial public offering in 2024.
Business Operations
Alumis operates as a single-reportable-segment biopharmaceutical company focused on research, clinical development, and eventual commercialization of immunology therapies. Its operations center on advancing clinical trials, conducting preclinical research, and managing regulatory interactions, with no approved commercial products as of the most recent public disclosures. Revenue generation to date has primarily consisted of collaboration revenue and investment income, with core expenditures directed toward research and development.
The company’s operations are primarily based in the United States and rely on a combination of internal scientific teams and external contract research organizations. Alumis controls its proprietary drug discovery platform and clinical assets, with ESK-001 as its most advanced candidate. The company does not currently report material joint ventures but maintains standard industry partnerships with clinical research, manufacturing, and regulatory service providers to support its development programs.
Strategic Position & Investments
Strategically, Alumis is focused on advancing ESK-001 through mid- to late-stage clinical development while expanding its immunology pipeline to address multiple autoimmune indications. Growth initiatives are centered on clinical trial execution, potential label expansion across diseases such as psoriasis and systemic lupus erythematosus, and the development of additional precision immunology candidates.
The company’s major investments are concentrated in internal research and development rather than external acquisitions. Alumis benefits from the continued strategic involvement of Third Rock Ventures, which has played a significant role in shaping the company’s scientific direction and capital strategy. Emerging areas of focus include next-generation immune pathway modulation and highly selective kinase inhibition, which the company views as key to improving therapeutic outcomes and safety profiles.
Geographic Footprint
Alumis is headquartered in South San Francisco, California, a major biotechnology hub within the United States. Its core research, development, and corporate functions are primarily based in this region, leveraging proximity to academic institutions, biotech talent, and industry partners.
While the company does not maintain large-scale international facilities, its clinical development programs have an international footprint through global clinical trial sites. These activities extend Alumis’s operational influence into parts of Europe and other regions involved in multinational clinical studies, supporting its long-term goal of addressing global autoimmune disease markets.
Leadership & Governance
Alumis was founded with the involvement of Third Rock Ventures, which remains influential through board representation and strategic guidance. The company’s leadership emphasizes rigorous science, disciplined capital allocation, and a long-term vision focused on delivering differentiated immunology therapies to patients.
Key members of the executive leadership team include:
- Martin Babler – President and Chief Executive Officer
- Andrew Mack – Chief Financial Officer
The leadership team’s strategic vision centers on building a sustainable immunology-focused biotechnology company by advancing high-quality clinical assets, maintaining strong governance practices, and aligning scientific innovation with unmet medical needs.